G. Wallenstein

442 total citations
15 papers, 308 citations indexed

About

G. Wallenstein is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, G. Wallenstein has authored 15 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in G. Wallenstein's work include Lung Cancer Treatments and Mutations (5 papers), HER2/EGFR in Cancer Research (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). G. Wallenstein is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), HER2/EGFR in Cancer Research (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). G. Wallenstein collaborates with scholars based in Germany, United States and Austria. G. Wallenstein's co-authors include Joanne van Ryn, M. Pairet, Gertraud Hanft, Thomas Meyer, Esther van den Berg, Bernard Zinman, C. Verhagen, Wolfgang Timmer, G. Scheuch and Odd Erik Johansen and has published in prestigious journals such as Journal of Clinical Oncology, Diabetologia and Pharmaceutical Research.

In The Last Decade

G. Wallenstein

15 papers receiving 291 citations

Peers

Countries citing papers authored by G. Wallenstein

Since Specialization

Citations

This map shows the geographic impact of G. Wallenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Wallenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Wallenstein more than expected).

Fields of papers citing papers by G. Wallenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Wallenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Wallenstein. The network helps show where G. Wallenstein may publish in the future.

Co-authorship network of co-authors of G. Wallenstein

This figure shows the co-authorship network connecting the top 25 collaborators of G. Wallenstein. A scholar is included among the top collaborators of G. Wallenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Wallenstein. G. Wallenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study 2021 ·Diabetologia ·Geert Jan Biessels, C. Verhagen, (unknown), Esther van den Berg, G. Wallenstein, Bernard Zinman, Mark A. Espeland, Odd Erik Johansen	37
2	Efficacy and Safety Results of the Afatinib Expanded Access Program 2017 ·Oncology and Therapy ·Edward S. Kim, Balázs Halmos, (unknown), Taral Patel, (unknown), Alexander I. Spira, A. Cseh, John McKay, G. Wallenstein, Kathryn F. Mileham	4
3	Strategic and Statistical Considerations on the QT Assessment of Volasertib 2017 ·Therapeutic Innovation & Regulatory Science ·G. Wallenstein, Beate Walter, Holger Fritsch, Tillmann Taube	2
4	Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study 2016 ·European Journal of Drug Metabolism and Pharmacokinetics ·Sabrina Wiebe, David Schnell, (unknown), Dietmar Ganßer, Anne Weber, G. Wallenstein, Atef Halabi, (unknown), Sven Wind	17
5	Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter‐ECG data from four randomised clinical trials 2014 ·International Journal of Clinical Practice ·Jens M. Hohlfeld, (unknown), (unknown), G. Wallenstein, (unknown), Eric Bateman	14
6	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·L. Rhoda Molife, Sarah Maria Rudman, Salma Alam, Daniel S.W. Tan, Hartmut Kristeleit, Gary Middleton, David Propper, (unknown), Peter Stopfer, Martina Uttenreuther‐Fischer, G. Wallenstein, Johann S. de Bono, James Spicer	15
7	Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study 2013 ·Investigational New Drugs ·Tim Eisen, Yaroslav Shparyk, Nicholas MacLeod, Robert J. Jones, G. Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, Arsène‐Bienvenu Loembé, Igor Bondarenko	48
8	Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study. 2012 ·Journal of Clinical Oncology ·Tim Eisen, Yaroslav Shparyk, Nicholas MacLeod, G. Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, (unknown), Igor Bondarenko	1
9	Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy. 2011 ·Journal of Clinical Oncology ·Hartmut Kristeleit, M. Puglisi, Gary Middleton, David Propper, Muireann Kelleher, Leonardo Trani, (unknown), G. Wallenstein, Peter Stopfer, (unknown), M. M. Uttenreuther-Fischer, Eric H. Bent, Dennis O’Brien, James Spicer, L Rhoda Molife	5
10	A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM). 2010 ·Journal of Clinical Oncology ·Leonardo Trani, (unknown), Sarah Maria Rudman, L Rhoda Molife, Gary Middleton, David Propper, Peter Stopfer, M. M. Uttenreuther-Fischer, G. Wallenstein, James Spicer	1
11	Lung Deposition of Radiolabeled Tiotropium in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease 2007 ·The Journal of Clinical Pharmacology ·Peter Brand, Thomas Meyer, (unknown), Wolfgang Timmer, (unknown), G. Wallenstein, G. Scheuch	38
12	Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers 2004 ·The Journal of Clinical Pharmacology ·Joanne van Ryn, (unknown), (unknown), (unknown), Gertraud Hanft, G. Wallenstein, (unknown), M. Pairet	44
13	Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS, the First Selective Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonist, Following Single Intravenous Administration in Healthy Volunteers 2004 ·Cephalalgia ·(unknown), (unknown), (unknown), (unknown), G. Wallenstein	76
14	“When Should A Substance Be Designated As Sensitizing For The Skin (“Sh”) Or For The Airways (“Sa”)"?” 2002 ·Pneumologie ·Axel Schnuch, Holger Lessmann, Karl‐Heinz Schulz, Dávid Becker, (unknown), Hans Drexler, S. Erdmann, (unknown), Helmut Greim, (unknown), R. Merget, Hans F. Merk, Dariusz Nowak, (unknown), (unknown), Wolfgang Uter, G. Wallenstein	3
15	Analyzing rich data using different methods provided by NONMEM: pharmacokinetics of telmisartan following intravenous infusion to healthy volunteers. 1999 ·Pharmaceutical Research ·G. Wallenstein, Joachim Stangier, Thomas M. Ludden	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact